Vanguard Personalized Indexing Management LLC Has $4.58 Million Stock Position in Sanofi $SNY

Vanguard Personalized Indexing Management LLC decreased its position in Sanofi (NASDAQ:SNY) by 2.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 94,856 shares of the company’s stock after selling 2,186 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Sanofi were worth $4,582,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC raised its holdings in Sanofi by 26.0% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 12,226 shares of the company’s stock valued at $591,000 after acquiring an additional 2,526 shares in the last quarter. Johnson Investment Counsel Inc. raised its holdings in Sanofi by 14.4% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 13,832 shares of the company’s stock valued at $668,000 after acquiring an additional 1,736 shares in the last quarter. Apollon Wealth Management LLC raised its holdings in Sanofi by 2.4% in the 2nd quarter. Apollon Wealth Management LLC now owns 18,268 shares of the company’s stock valued at $883,000 after acquiring an additional 430 shares in the last quarter. Natural Investments LLC acquired a new position in shares of Sanofi in the 2nd quarter worth approximately $232,000. Finally, Aberdeen Group plc raised its holdings in shares of Sanofi by 65.1% in the 2nd quarter. Aberdeen Group plc now owns 323,582 shares of the company’s stock worth $15,632,000 after buying an additional 127,534 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Barclays reissued an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Sanofi presently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Stock Up 1.5%

NASDAQ SNY opened at $48.80 on Tuesday. The firm has a market cap of $119.83 billion, a PE ratio of 11.73, a price-to-earnings-growth ratio of 1.17 and a beta of 0.51. Sanofi has a one year low of $44.62 and a one year high of $60.12. The stock’s 50 day simple moving average is $48.29 and its 200 day simple moving average is $49.70. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm’s revenue was down 7.0% on a year-over-year basis. During the same quarter last year, the company earned $1.73 earnings per share. As a group, sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.